Antibody

6개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved6 programs
AntibodyLimited DatastaleRochePhase 3

Ocrelizumab, Rituximab, Ofatumumab (Anti-CD20 therapies, Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab))

Relapsing-Remitting Multiple Sclerosis (RRMS); Anti-CD20 Therapy · CD20

#CD20#Antibody#Phase3#monoclonal-antibody#Relapsing-RemittingMultipleScler+3
Trials 40Status Recruiting
AntibodyLimited DatastaleBiogenPhase 2

Natalizumab (Natalizumab)

Crohn's Disease · Multiple Sclerosis, Relapsing-Remitting

#MultipleSclerosisRelapsing-Remit#Antibody#Phase2#monoclonal-antibody#CrohnsDisease+1
Trials 4Status Active
AntibodyLimited DatastaleScripps HealthPreclinical

Cyclophosphamide/Rituximab (Cyclophosphamide/Rituximab)

Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis, Relapsing-Remitting

#MultipleSclerosisRelapsing-Remit#Antibody#Preclinical#monoclonal-antibody#MultipleSclerosis+2
Trials 1Status Discontinued
AntibodyLimited DatastaleZenas BioPharma (USA), LLCPhase 2

Obexelimab (Obexelimab)

Relapsing Multiple Sclerosis · Relapsing Multiple Sclerosis

#RelapsingMultipleSclerosis#Antibody#Phase2#monoclonal-antibody#Zenas
Trials 1Status Recruiting
AntibodyLimited DatastaleRennes University HospitalPhase 3

Perfusion of treatment Ocrelizumab (Perfusion of treatment Ocrelizumab)

Multiple Sclerosis; Relapsing-remitting Multiple Sclerosis · Multiple Sclerosis

#MultipleSclerosis#Antibody#Phase3#monoclonal-antibody#Relapsing-remittingMultipleScler+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 3

Perfusion of treatment Rituximab (Perfusion of treatment Rituximab)

Multiple Sclerosis; Relapsing-remitting Multiple Sclerosis · Multiple Sclerosis

#MultipleSclerosis#Antibody#Phase3#monoclonal-antibody#Relapsing-remittingMultipleScler+1
Trials 1Status Recruiting